FIELD: medicine.
SUBSTANCE: invention relates to a compound having structure I or its pharmaceutically acceptable salt that inhibit fatty acid synthase (FASN) and that can be used in the treatment of cancer. In the formula I, L-Ar is 
or 
; Ar is 
; R1 is -CN or -O-(C1-C4 alkyl) optionally substituted with one or more halogens; each R2 is hydrogen; R3 is H or F; R21 is C1-C4 alkyl; R22 is H or C1-C2 alkyl; R24 is -O-(C1-C4 alkyl), -O-(C1-C4 alkyl)-O-(C1-C4 alkyl) or -O-(4-6-element heterocycle), wherein R24 is optionally substituted with one or more hydroxyls or halogens; and R25 is C1-C4 alkyl. The invention also relates to a pharmaceutical composition containing the specified compounds and a method for treatment of cancer characterized in violation of regulation of a fatty acid synthase path.
EFFECT: obtaining a compound for the treatment of cancer.
26 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | 2014 |
|
RU2686323C2 |
| NOVEL COMPOUNDS AND FASN INHIBITION COMPOSITIONS | 2014 |
|
RU2737434C2 |
| DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | 2015 |
|
RU2742305C2 |
| HETEROAROMATIC COMPOUNDS SUITABLE IN THERAPY | 2018 |
|
RU2770363C2 |
| OXADIAZOLE-BASED CHANNEL INHIBITORS WITH TRANSIENT POTENTIAL | 2019 |
|
RU2818244C2 |
| PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS | 2015 |
|
RU2689788C2 |
| COMPOUNDS TARGETING BRM AND RELATED USES THEREOF | 2019 |
|
RU2797832C2 |
| ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2020 |
|
RU2821414C2 |
| HETEROCYCLIC INHIBITORS OF MCT4 | 2017 |
|
RU2771875C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
